Chang Gung Memorial Hospital: Carcinoma, Hepatocellular trials

The registry lists 18 Carcinoma, Hepatocellular studies with Chang Gung Memorial Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 2 9Phase 3 1Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingNCT07827807Phase 2
• Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999707Phase 2
• Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999694Phase 2
• Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 Cm and Microvascular InvasionRecruitingNCT06628661
• Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and BevacizumabRecruitingNCT06605664Phase 2
• Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing RadiotherapyRecruitingNCT06379256
• Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06339424Phase 2
• Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular CarcinomaRecruitingNCT06327269Early Phase 1
• Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular CarcinomaRecruitingNCT06034977Phase 2
• Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular CarcinomaCompletedNCT06368349
• Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical TrialActive, not recruitingNCT06193733Phase 2
• The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular CarcinomaCompletedNCT04296058
• Arterial Base Fluorescence Segmental Positive StainingCompletedNCT04266548Not applicable
• Hypermethylation of VTRNA2-1 Promoter in HCC OutcomeCompletedNCT04177316
• Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT GenotypeTerminatedNCT03608878Phase 2
• Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular CarcinomaStatus unknownNCT02640924Phase 3
• Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular CarcinomaStatus unknownNCT02504983Phase 4
• Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma RecurrenceCompletedNCT02447679Phase 2